Home / Business and Economy / Weight-loss drug access may hit 50% ceiling
Weight-loss drug access may hit 50% ceiling
17 Apr
Summary
- Half of overweight individuals may not access weight-loss drugs.
- Healthcare systems and cost are key barriers to access.
- Production ramp-up for drugs is expensive and slow.
Eli Lilly CEO David Ricks stated on Friday that complexities within healthcare systems and financial limitations may restrict weight-loss drug access to approximately 50% of eligible individuals. Currently, only about 10% of overweight or obese people are using GLP-1 drugs. Ricks suggested that an estimated 50% market penetration, representing around 500 million people globally, could be a realistic ceiling, similar to the 40-50% access rate for statins.
He emphasized that increasing production to meet even this potential demand is a significant challenge, describing the process as "expensive and slow." Ricks noted that treating the current 21-22 million patients represents only a fraction of the potential market. The introduction of oral weight-loss pills, such as Lilly's Foundayo and Novo Nordisk's Wegovy, offers a needle-free alternative, though cost remains a major hurdle for many.
